Companies › Valenta Pharm JSC
8 active drug programs in 12 registered trials: 6 Phase 1, 3 Phase 2, 2 Phase 4, 1 Phase 3; Respiratory, Gastroenterology, Infectious disease, Psychiatry; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vespireit 5-HT1A receptor agonist | HTR1A | Phase 4 | Vertigo | Dec 2026 |
| Ranquilon | – | Phase 4 | Anxiety | Dec 2027 |
| 4-MUST (trimebutine 4-methylumbelliferyl sulfate) Trimebutine derivative; prokinetic agent acting as TRPV1 agonist and 5-HT4 receptor agonis | TRPV1, HTR4 | Phase 3 | Chronic Cholecystitis | Dec 2026 |
| Grammidin with anesthetic Local anesthetic and antimicrobial topical spray | – | Phase 2 | Pharyngitis Acute | Dec 2026 |
| Ingavirin Forte Combination of imidazolylethanamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclope | – | Phase 2 | Influenza | Dec 2027 |
| Benoxinate Sodium channel alpha subunit blocker | Ion channels | Phase 1 | Pharyngitis | Dec 2026 |
| Grammidin, a metered dose topical spray Antimicrobial combination containing gramicidin S and cetylpyridinium chloride | – | Phase 1 | Pharyngitis | Dec 2026 |
| Trimedat® 76.95 mg orally disintegrating tablets Trimebutine maleate - prokinetic agent | – | Phase 1 | Irritable Bowel Syndrome | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06857890 | Benoxinate | Phase 1 | Pharyngitis | Respiratory | Dec 2026 |
| NCT06859281 | Grammidin, a metered dose topical spray | Phase 1 | Pharyngitis | Respiratory | Dec 2026 |
| NCT07421011 | Trimedat® 76.95 mg orally disintegrating tablets | Phase 1 | Irritable Bowel Syndrome | Gastroenterology | Dec 2026 |
| NCT06842966 | 4-MUST (trimebutine 4-methylumbelliferyl sulfate) | Phase 2 | Chronic Cholecystitis | Gastroenterology | Dec 2026 |
| NCT06843018 | Grammidin with anesthetic | Phase 2 | Pharyngitis Acute | Respiratory | Dec 2026 |
| NCT06321341 | Vespireit | Phase 4 | Vertigo | Neurology | Dec 2026 |
| NCT07594977 | 4-MUST (trimebutine 4-methylumbelliferyl sulfate) | Phase 1 | Chronic Cholecystitis | Gastroenterology | Jun 2027 |
| NCT07420985 | Ingavirin Forte | Phase 2 | Influenza | Infectious disease | Dec 2027 |
| NCT07645534 | Ingavirin Forte | Phase 1 | Influenza | Infectious disease | Dec 2027 |
| NCT07645534 | Ingavirin Forte | Phase 1 | Influenza | Infectious disease | Dec 2027 |
| NCT07595003 | 4-MUST (trimebutine 4-methylumbelliferyl sulfate) | Phase 3 | Chronic Cholecystitis | Gastroenterology | Dec 2027 |
| NCT06843044 | Ranquilon | Phase 4 | Anxiety | Psychiatry | Dec 2027 |
Shionogi Chiesi Farmaceutici Vertex Pharmaceuticals Teva Branded Pharmaceutical Products R&D Beijing Continent Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.